- Email: [email protected]
Correlates of health-related quality of life in women with severe facial pigmentary disorders
P277
P279
NEW APPROACH FOR THE ASSESSMENT OF ENVIRONMENTAL STRESS AND ITS PREVENTION Isabelle Besne, PhD, L’Ore´al Recherche, Clichy, France, Fanny Plismy, PhmD, L’Oreal Recherche, Chevilly Larue, France, Christel Liviero, PhmD, Lancoˆ me International, Paris, France, Philippe Catroux, PhmD, L’Oreal Recherche, Aulnay sous bois, France It is now clear that different factors such as environmental or psychological stress may induce changes in cutaneous tolerance making the skin more reactive with clinical signs of discomfort (itching and stinging). Pollutant-induced sick building syndrome, for example, which includes a relatively limited group of non specific symptoms, is manifested by irritation of mucous membranes and skin. We hypothesized that part of these effects might be related to calcitonin gene related peptide (CGRP) released locally in response to pollution. To investigate this hypothesis, we developed a new in vitro model made up of a reconstructed human epidermis co-cultured with neuronal sensitive cells in a twocompartment chamber. Different combinations of cadmium (representative of outdoor pollutants) and formaldehyde (representative of indoor pollutants) were applied topically on epidermis at sub-cytotoxic concentrations. The release of CGRP by cultured neurones was significantly increased after 24 hour contact with pollutants (1220 ⫾ 441 pg/ml versus 46 ⫾ 18 pg/ml in control, p ⬍ 0.05)). Using the same model, we evaluated the effect of a Moringa oleifera extract. Applying 1% extract was shown to significantly reduce pollutant-induced release of CGRP (233 ⫾ 25 pg/ml, p ⬍ 0.05). On the other hand, a clinical study was performed on 50 women using stinging test with lactic acid. The soothing effect of a cosmetic cream containing Moringa oleifera extract was assessed. After 28 day treatment, the irritant score was decreased by 66 % (p ⬍ 0.05) in women treated with the cream containing Moringa oleifera. In the present study, we evidenced for the first time that pollutants induced the release of CGRP by neurons cocultured with reconstructed human epidermis. Moreover, both in vitro and clinical results clearly showed the beneficial effect of a Moringa oleifera extract used alone and in a product designed for lowering the impact of environmental stress on the skin.
CLINICAL EFFECT OF A THREE-DAY APPLICATION OF A COMMERCIAL DEODORANT ON AXILLA MALODOR INTENSITY, MICROBIAL POPULATION LEVEL, AND LONGEVITY OF FRAGRANCE EXPRESSION Anthony C Lanzalaco, PhD, Procter & Gamble, Cincinnati, OH, United States, Heather Rocchetta, PhD, Procter & Gamble, Cincinnati, OH, United States, Sheri Gordon, MS, Procter & Gamble, Cincinnati, OH, United States, Janie Kolodzik, BS, Procter & Gamble, Cincinnati, OH, United States Axillary odor can seriously compromise a person’s social and work life. In a poster (P320) that we presented at the 61st Annual Meeting of the AAD, it was shown that the effectiveness of basic hygiene measures for controlling axillary odor were enhanced following a single application of a commercial deodorant product. This work presents the results of clinical studies that were conducted to assess the ability of deodorant products, with and without perfumes, to affect bacterial levels and reduce axillary odor following 3 days of use. Two clinical trials were conducted at the Hill Top Research Center. In each study 20 male volunteers completed a 12-day conditioning period in which they did not use a deodorant product. At the end of this period, subjects were entered into the 3-day treatment phase if 24 hours after a controlled soap wash they received an axillary odor score ⬎ 4 (0-10 scale). Study 1 evaluated a commercial product containing masking perfumes while study 2 assessed the same formulation, minus the masking perfumes. In each study, 0.4 grams of product was applied daily to each axilla using a controlled application procedure. Odor scores were obtained at baseline, and 6, 12 and 24 hrs after the 3rd day’s treatment. Fragrance intensity (0-5 scale) was assessed immediately after product application and 6, 12 and 24 hrs after the 3rd day’s treatment. Microbial samples were collected via axillary cup scrubs at baseline and 24 hrs after the 3rd day’s treatment. In both studies, the test products significantly reduced total aerobic bacteria levels and Corynebacteria levels on the axilla. In study 1, the perfumed product reduced baseline axilla odor by 47% at 6 hrs, and 26% at both 12 and 24 hrs. Axilla fragrance intensity declined by 46% at 6 hrs, 75% at 12 hrs, and 83% at 24 hrs. In study 2, the perfume free product reduced baseline odor by 34% at 6 hrs, 26% at 12 hrs and 19% at 24 hrs. The results show that both products controlled odor-causing bacteria for at least 24 hrs after use. The presence of perfume boosted odor reductions for at least 6 hrs after application. However, as fragrance levels decreased, odor reductions approached those seen for the perfume free product. This work provides additional proof that by combining effective odor masking with the ability to control odor-causing bacteria, commercial deodorants can significantly boost the effectiveness of a person’s daily hygiene practices.
Disclosure not available at press time. 100% is sponsored by L’Ore´al
I am a full time employee of the Procter & Gamble Company. 100% is Sponsored by Procter & Gamble
P278 MICRO-IMAGING OF SKIN WITH INNOVATIVE METHODOLOGY: VALUABLE FOR SKIN OF COLOR Warren Wallo, MS, Johnson & Johnson Consume and Personal Products Worldwide, Skillman, NJ, United States, Geoffrey Smith, BS, Johnson & Johnson Consume and Personal Products Worldwide, Skillman, NJ, United States, Michael Luedtke, BS, Johnson & Johnson Consume and Personal Products Worldwide, Skillman, NJ, United States, Ellen S. Kurtz, PhD, Johnson & Johnson Consume and Personal Products Worldwide, Skillman, NJ, United States There is tremendous value to both the clinician and the clinical researcher in documenting and tracking changes in cutaneous characteristics for diagnosis of skin disorders and monitoring patients with various skin conditions during treatment. It is important to document the presence of dry or ashen skin, erythema and variations in pigmentation, as well as the improvement of these conditions with a variety of dermatological procedures and treatments. To address this need, we have developed techniques to document these clinical features on the cutaneous surface and to accurately monitor significant changes. These innovative methodologies included specialized epiluminescence microscopy (ELM) coupled with high-resolution digital imaging and video-microscopy at numerous magnifications, as well as a standardized adhesive skin-sampling system. The high-resolution imaging techniques have been applied to a full range of skin phototypes and have proven especially valuable for skin of color. Textural features such as adhesion and desquamation of corneocytes and skin dermatoglyphic patterns are readily observed and changes can be measured and documented over time. Distribution and intensity of skin pigment, including post-inflammatory hyperpigmentation and hypopigmentation in skin of color can be readily evaluated. The visibility and distribution of hair can be visualized with extremely high detail and resolution. These methods have been utilized together with side-by-side comparison of images of patients throughout treatment and allow for critical evaluation of changes in cutaneous characteristics with high sensitivity. The improvements in various cutaneous parameters were clinically demonstrated with oatmeal and soy containing topical preparations. These novel imaging techniques provide the clinician with tools for tracking patients over time and also provides valuable documentation for monitoring skin conditions and evaluating the effects of procedures and treatments in improving the appearance of the skin. All of the authors are employees of Johnson & Johnson Consumer Companies, Inc. These studies were supported in full by Johnson & Johnson Consumer Companies, Inc.
MARCH 2004
P280 CORRELATES OF HEALTH-RELATED QUALITY OF LIFE IN WOMEN WITH SEVERE FACIAL PIGMENTARY DISORDERS Rajesh Balkrishnan, PhD, Division of Management and Policy Sciences, University of Texas School of Public Health, Houston, TX, United States, Amy McMichael, MD, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, United States, Anne Buoloc, MD, PhD, Vichy Laboratoires Asnieres and Tarnier Hospital, Paris, France, Steven Feldman, MD, PhD, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, United States Objective: Facial appearance plays a large role of self-perception and interactions with others. Visible facial skin lesions are a common condition. This study assessed factors associated with Health-related Quality of Life in women with severe facial pigmentary disorders. Methods: The study included 73 women with either 1 or more of the following conditions: acne, dermatosis papulosis, hypopigmentation, lentigenes, melasma, rosacea, vascular proliferations and other facial scars. The Skindex-16 was used as a measure of HRQOL. Fear of Negative Evaluation (FNE) were assessed to determine if self-perception characteristics relate to HRQOL. Results: There were strong correlations in both bivariate and multivariate analyses among increased FNE, heightened perception of QOL without the facial condition and lower overall HRQOL (p ⬍ 0.05 and p ⬍ 0.01 respectively). There were no differences in HRQOL by type of facial condition, as well as no effects of the area covered by the condition on HRQOL. Interestingly, women not using foundations represented only 10% of the study population and had better HRQOL than women who did use foundations. Conclusions: Severe facial pigmentary disorders of any cause have a significant impact on women’s quality of life, and the effect of these lesions is mediated in part by psychological characteristics related to self-perception and self-presentation. Dr Feldman has received grant support from L’oreal Research This study has been funded by Dermablend-Vichy Laboratoires. Dermatopharmacology/Cosmeceuticals
J AM ACAD DERMATOL
P73
P279
NEW APPROACH FOR THE ASSESSMENT OF ENVIRONMENTAL STRESS AND ITS PREVENTION Isabelle Besne, PhD, L’Ore´al Recherche, Clichy, France, Fanny Plismy, PhmD, L’Oreal Recherche, Chevilly Larue, France, Christel Liviero, PhmD, Lancoˆ me International, Paris, France, Philippe Catroux, PhmD, L’Oreal Recherche, Aulnay sous bois, France It is now clear that different factors such as environmental or psychological stress may induce changes in cutaneous tolerance making the skin more reactive with clinical signs of discomfort (itching and stinging). Pollutant-induced sick building syndrome, for example, which includes a relatively limited group of non specific symptoms, is manifested by irritation of mucous membranes and skin. We hypothesized that part of these effects might be related to calcitonin gene related peptide (CGRP) released locally in response to pollution. To investigate this hypothesis, we developed a new in vitro model made up of a reconstructed human epidermis co-cultured with neuronal sensitive cells in a twocompartment chamber. Different combinations of cadmium (representative of outdoor pollutants) and formaldehyde (representative of indoor pollutants) were applied topically on epidermis at sub-cytotoxic concentrations. The release of CGRP by cultured neurones was significantly increased after 24 hour contact with pollutants (1220 ⫾ 441 pg/ml versus 46 ⫾ 18 pg/ml in control, p ⬍ 0.05)). Using the same model, we evaluated the effect of a Moringa oleifera extract. Applying 1% extract was shown to significantly reduce pollutant-induced release of CGRP (233 ⫾ 25 pg/ml, p ⬍ 0.05). On the other hand, a clinical study was performed on 50 women using stinging test with lactic acid. The soothing effect of a cosmetic cream containing Moringa oleifera extract was assessed. After 28 day treatment, the irritant score was decreased by 66 % (p ⬍ 0.05) in women treated with the cream containing Moringa oleifera. In the present study, we evidenced for the first time that pollutants induced the release of CGRP by neurons cocultured with reconstructed human epidermis. Moreover, both in vitro and clinical results clearly showed the beneficial effect of a Moringa oleifera extract used alone and in a product designed for lowering the impact of environmental stress on the skin.
CLINICAL EFFECT OF A THREE-DAY APPLICATION OF A COMMERCIAL DEODORANT ON AXILLA MALODOR INTENSITY, MICROBIAL POPULATION LEVEL, AND LONGEVITY OF FRAGRANCE EXPRESSION Anthony C Lanzalaco, PhD, Procter & Gamble, Cincinnati, OH, United States, Heather Rocchetta, PhD, Procter & Gamble, Cincinnati, OH, United States, Sheri Gordon, MS, Procter & Gamble, Cincinnati, OH, United States, Janie Kolodzik, BS, Procter & Gamble, Cincinnati, OH, United States Axillary odor can seriously compromise a person’s social and work life. In a poster (P320) that we presented at the 61st Annual Meeting of the AAD, it was shown that the effectiveness of basic hygiene measures for controlling axillary odor were enhanced following a single application of a commercial deodorant product. This work presents the results of clinical studies that were conducted to assess the ability of deodorant products, with and without perfumes, to affect bacterial levels and reduce axillary odor following 3 days of use. Two clinical trials were conducted at the Hill Top Research Center. In each study 20 male volunteers completed a 12-day conditioning period in which they did not use a deodorant product. At the end of this period, subjects were entered into the 3-day treatment phase if 24 hours after a controlled soap wash they received an axillary odor score ⬎ 4 (0-10 scale). Study 1 evaluated a commercial product containing masking perfumes while study 2 assessed the same formulation, minus the masking perfumes. In each study, 0.4 grams of product was applied daily to each axilla using a controlled application procedure. Odor scores were obtained at baseline, and 6, 12 and 24 hrs after the 3rd day’s treatment. Fragrance intensity (0-5 scale) was assessed immediately after product application and 6, 12 and 24 hrs after the 3rd day’s treatment. Microbial samples were collected via axillary cup scrubs at baseline and 24 hrs after the 3rd day’s treatment. In both studies, the test products significantly reduced total aerobic bacteria levels and Corynebacteria levels on the axilla. In study 1, the perfumed product reduced baseline axilla odor by 47% at 6 hrs, and 26% at both 12 and 24 hrs. Axilla fragrance intensity declined by 46% at 6 hrs, 75% at 12 hrs, and 83% at 24 hrs. In study 2, the perfume free product reduced baseline odor by 34% at 6 hrs, 26% at 12 hrs and 19% at 24 hrs. The results show that both products controlled odor-causing bacteria for at least 24 hrs after use. The presence of perfume boosted odor reductions for at least 6 hrs after application. However, as fragrance levels decreased, odor reductions approached those seen for the perfume free product. This work provides additional proof that by combining effective odor masking with the ability to control odor-causing bacteria, commercial deodorants can significantly boost the effectiveness of a person’s daily hygiene practices.
Disclosure not available at press time. 100% is sponsored by L’Ore´al
I am a full time employee of the Procter & Gamble Company. 100% is Sponsored by Procter & Gamble
P278 MICRO-IMAGING OF SKIN WITH INNOVATIVE METHODOLOGY: VALUABLE FOR SKIN OF COLOR Warren Wallo, MS, Johnson & Johnson Consume and Personal Products Worldwide, Skillman, NJ, United States, Geoffrey Smith, BS, Johnson & Johnson Consume and Personal Products Worldwide, Skillman, NJ, United States, Michael Luedtke, BS, Johnson & Johnson Consume and Personal Products Worldwide, Skillman, NJ, United States, Ellen S. Kurtz, PhD, Johnson & Johnson Consume and Personal Products Worldwide, Skillman, NJ, United States There is tremendous value to both the clinician and the clinical researcher in documenting and tracking changes in cutaneous characteristics for diagnosis of skin disorders and monitoring patients with various skin conditions during treatment. It is important to document the presence of dry or ashen skin, erythema and variations in pigmentation, as well as the improvement of these conditions with a variety of dermatological procedures and treatments. To address this need, we have developed techniques to document these clinical features on the cutaneous surface and to accurately monitor significant changes. These innovative methodologies included specialized epiluminescence microscopy (ELM) coupled with high-resolution digital imaging and video-microscopy at numerous magnifications, as well as a standardized adhesive skin-sampling system. The high-resolution imaging techniques have been applied to a full range of skin phototypes and have proven especially valuable for skin of color. Textural features such as adhesion and desquamation of corneocytes and skin dermatoglyphic patterns are readily observed and changes can be measured and documented over time. Distribution and intensity of skin pigment, including post-inflammatory hyperpigmentation and hypopigmentation in skin of color can be readily evaluated. The visibility and distribution of hair can be visualized with extremely high detail and resolution. These methods have been utilized together with side-by-side comparison of images of patients throughout treatment and allow for critical evaluation of changes in cutaneous characteristics with high sensitivity. The improvements in various cutaneous parameters were clinically demonstrated with oatmeal and soy containing topical preparations. These novel imaging techniques provide the clinician with tools for tracking patients over time and also provides valuable documentation for monitoring skin conditions and evaluating the effects of procedures and treatments in improving the appearance of the skin. All of the authors are employees of Johnson & Johnson Consumer Companies, Inc. These studies were supported in full by Johnson & Johnson Consumer Companies, Inc.
MARCH 2004
P280 CORRELATES OF HEALTH-RELATED QUALITY OF LIFE IN WOMEN WITH SEVERE FACIAL PIGMENTARY DISORDERS Rajesh Balkrishnan, PhD, Division of Management and Policy Sciences, University of Texas School of Public Health, Houston, TX, United States, Amy McMichael, MD, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, United States, Anne Buoloc, MD, PhD, Vichy Laboratoires Asnieres and Tarnier Hospital, Paris, France, Steven Feldman, MD, PhD, Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, NC, United States Objective: Facial appearance plays a large role of self-perception and interactions with others. Visible facial skin lesions are a common condition. This study assessed factors associated with Health-related Quality of Life in women with severe facial pigmentary disorders. Methods: The study included 73 women with either 1 or more of the following conditions: acne, dermatosis papulosis, hypopigmentation, lentigenes, melasma, rosacea, vascular proliferations and other facial scars. The Skindex-16 was used as a measure of HRQOL. Fear of Negative Evaluation (FNE) were assessed to determine if self-perception characteristics relate to HRQOL. Results: There were strong correlations in both bivariate and multivariate analyses among increased FNE, heightened perception of QOL without the facial condition and lower overall HRQOL (p ⬍ 0.05 and p ⬍ 0.01 respectively). There were no differences in HRQOL by type of facial condition, as well as no effects of the area covered by the condition on HRQOL. Interestingly, women not using foundations represented only 10% of the study population and had better HRQOL than women who did use foundations. Conclusions: Severe facial pigmentary disorders of any cause have a significant impact on women’s quality of life, and the effect of these lesions is mediated in part by psychological characteristics related to self-perception and self-presentation. Dr Feldman has received grant support from L’oreal Research This study has been funded by Dermablend-Vichy Laboratoires. Dermatopharmacology/Cosmeceuticals
J AM ACAD DERMATOL
P73